Drs. Bossi, Wallis on Prostate Irradiation in Men With De Novo, Low-Volume mCSPC

Alberto Bossi, MD, Gustave Roussy Cancer Institute, and Christopher Wallis, MD, PhD, University of Toronto, break down the results of the PEACE-1 study presented as a late-breaking abstract at the ASCO 2023 Annual Meeting.

PEACE-1 initially demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone improves both OS and rPFS in men with de novo mCSPC. Dr. Bossi’s most recent analysis examines the second pre-planned primary endpoint of PEACE-1 in the low-volume population: the impact of prostate irradiation in men receiving intensified systemic treatment.

View their continued discussions on the Synergistic Effects of Abiraterone, Radiotherapy for De Novo mCSPC and the Right Patients for Radiotherapy When Presenting With De Novo mCSPC.